文献速递其他结缔组织病

吡啶斯的明治疗系统性硬化症胃肠道症状

Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis.
PubMed 文献 · Semin Arthritis Rheum · 2018-01-05

该病例系列回顾了10年间在四级转诊中心接受吡啶斯的明治疗难治性胃肠道症状的31例系统性硬化症患者,51.6%报告症状改善,便秘是最常改善的症状,15/31例出现不良反应,最常见为腹泻。

要点

  • 31例系统性硬化症患者接受吡啶斯的明治疗至少4周,51.6%报告症状改善。
  • 便秘是最常改善的症状,20例便秘患者中6例改善。
  • 15/31例报告不良反应,最常见为腹泻;81.3%有症状获益者继续用药。

核心结论

  • 吡啶斯的明对系统性硬化症患者的多种胃肠道症状有治疗前景,尤其对难治性便秘患者。
  • 尽管不良反应可能限制其使用,但多数获得获益的患者选择继续治疗。

研究设计与样本

  • 研究为病例系列,回顾性分析了10年间在四级转诊中心接受吡啶斯的明治疗难治性胃肠道症状的系统性硬化症患者。
  • 共纳入31例接受吡啶斯的明治疗至少4周的患者。
  • 应答者定义为持续使用吡啶斯的明至少4周且患者或主治医师记录的临床获益有文档记载。

主要发现

  • 31例接受吡啶斯的明治疗至少4周的患者中,51.6%报告症状改善。
  • 便秘是治疗前患病率最高的可改善症状,20例便秘患者中6例报告改善。
  • 31例患者中15例报告不良反应,最常见为腹泻。
  • 随访中位时间126天(范围28-506天),报告症状获益的患者中81.3%继续使用吡啶斯的明,总体患者中58.1%继续使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/PURPOSE: Symptoms of gastrointestinal dysmotility are common among patients with systemic sclerosis (SSc), and the management of severe cases is often limited by a relative lack of effective interventions. The objective of this case series was to review our experience with pyridostigmine as a treatment for patients with SSc and symptomatic gastrointestinal disease. METHODS: This study evaluated rates of symptom improvement, side effects, medication adherence, and dose ranges for SSc patients prescribed pyridostigmine for refractory gastrointestinal symptoms over a 10-year period at a quaternary referral center. Patients were defined as responders if they remained on pyridostigmine for at least 4 weeks and clinical benefit was documented by the recorded response of the patient or by the treating physician RESULTS: Of 31 patients treated with pyridostigmine for at least 4 weeks, 51.6% reported symptomatic improvement. Constipation was the most commonly improved symptom based on prevalence prior to therapy (noted by 6/20 patients suffering with constipation). Fifteen of 31 patients reported adverse effects, most commonly diarrhea. Throughout the duration of follow-up (median 126 days, range: 28-506 days), pyridostigmine was continued by 81.3% of patients who reported symptomatic benefit and 58.1% of patients overall. CONCLUSIONS: Pyridostigmine holds promise for the treatment of various gastrointestinal symptoms in SSc patients, particularly in patients with refractory constipation. Though side effects may limit its use, most patients who experienced benefit chose to continue therapy.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Ahuja NK, Mische L, Clarke JO, et al. Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis. Semin Arthritis Rheum. 2018. PMID: 29397195. doi:10.1016/j.semarthrit.2017.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。